Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis
- PMID: 17163303
- DOI: 10.2165/00044011-200626110-00008
Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis
Abstract
We report the case of a patient with refractory ulcerative colitis who developed cholestatic acute liver damage after a single infusion of infliximab. Unusual aspects of this case were the early onset (after the first administration) of liver damage and the absence of antinuclear antibodies, alcohol intake, hepatotoxic drugs and all known viral and metabolic causes of hepatic injury. Moreover, no serological or morphological findings of primary sclerosing cholangitis were observed. The patient's liver damage resolved spontaneously within 6 weeks. Although a direct relationship between administration of infliximab and onset of acute liver damage could not be definitely established, our case suggests that infliximab may induce direct liver damage, the course of which is similar to acute cholestatic hepatitis and resolves following withdrawal of the drug.
Similar articles
-
Infliximab for ulcerative colitis following liver transplantation.Eur J Gastroenterol Hepatol. 2007 Mar;19(3):277-80. doi: 10.1097/MEG.0b013e3280116ccc. Eur J Gastroenterol Hepatol. 2007. PMID: 17301656
-
Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.World J Gastroenterol. 2013 Jan 28;19(4):590-3. doi: 10.3748/wjg.v19.i4.590. World J Gastroenterol. 2013. PMID: 23382642 Free PMC article.
-
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5. Acta Dermatovenerol Croat. 2016. PMID: 27149138
-
Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature.J Crohns Colitis. 2013 Mar;7(2):e61-5. doi: 10.1016/j.crohns.2012.04.005. Epub 2012 Apr 30. J Crohns Colitis. 2013. PMID: 22552273 Review.
-
Infliximab for the treatment of acute exacerbations of ulcerative colitis.Health Technol Assess. 2010 May;14 Suppl 1:9-15. doi: 10.3310/hta14Suppl1/02. Health Technol Assess. 2010. PMID: 20507798 Review.
Cited by
-
Infliximab-related hepatitis: a case study and literature review.Dig Dis Sci. 2013 Nov;58(11):3362-7. doi: 10.1007/s10620-013-2698-6. Epub 2013 May 5. Dig Dis Sci. 2013. PMID: 23645381 Review. No abstract available.
-
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.Int J Mol Sci. 2018 Jul 27;19(8):2199. doi: 10.3390/ijms19082199. Int J Mol Sci. 2018. PMID: 30060508 Free PMC article. Review.
-
Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.Dig Dis Sci. 2012 Jun;57(6):1604-8. doi: 10.1007/s10620-012-2159-7. Epub 2012 Apr 26. Dig Dis Sci. 2012. PMID: 22535279 Free PMC article.
-
Lipid nanoparticles silence tumor necrosis factor α to improve wound healing in diabetic mice.Bioeng Transl Med. 2018 Dec 20;4(1):75-82. doi: 10.1002/btm2.10123. eCollection 2019 Jan. Bioeng Transl Med. 2018. PMID: 30680320 Free PMC article.
-
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Clin Gastroenterol Hepatol. 2013. PMID: 23333219 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical